Evaluation of a new substance (isobutylamido thiazolyl resorcinolcream) compared to the use of hydroquinone 4% cream to treat facial blemishes
Not Applicable
- Conditions
- Melasma
- Registration Number
- RBR-87kphy
- Lead Sponsor
- Faculdade de Medicina de Botucatu (FMB - Unesp)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Data analysis completed
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
Women with facial melasma 18 to 50 years old, Fitzpatrick's phototypes II to V.
Exclusion Criteria
Pregnant and lactating women; women with vitiligo or photosensitizing diseases; individuals who are using other whitening substances and those who refuse to be photographed; photoexposed women and menopausal women (after 50 years).
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of the severity of melasma assessed using the mMASI score (modified Melasma Area and Severity Index); evaluation at T30 (30th day) and T90 (90th day of treatment); a percentage reduction of at least 10% is expected in T90 compared to T0.<br>
- Secondary Outcome Measures
Name Time Method Secondary outcomes will be evaluated through MELASQoL, dermatoscopy and clinical evaluation by the participant and the researcher, both at T0 and T60 and T90.